Download PDF
ergopraxis 2022; 15(01): 20-25
DOI: 10.1055/a-1660-9718
Therapie

Folgenschwerer Konsum – Fetale Alkoholspektrumstörung

Mirjam N. Landgraf∗
› Further Information
   Permissions and Reprints

Mütterlicher Alkoholkonsum während der Schwangerschaft kann zu neurokognitiven Beeinträchtigungen und morphologischen Veränderungen beim Kind führen, die unter dem Oberbegriff „Fetale Alkoholspektrumstörung“ (FASD) zusammengefasst werden. Die FASD geht mit erheblichen Einschränkungen der selbstständigen Alltags- und Lebensgestaltung einher – im Kindes- und Jugendalter ebenso wie im Erwachsenenalter.



Publication History

Article published online:
04 January 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literaturverzeichnis

  • 1 Landgraf MN, Albers L, Rahmsdorf B. et al Fetal alcohol spec-trum disorders (FASD) – What we know and what we should know – The knowledge of German health professionals and parents. Eur J PaediatrNeurol 2018; 22: 507-515
    Google Scholar
  • 2 Kraus L, Seitz NN, Shield KD. et al Quantifying harms to others due to alcohol consumption in Germany: a register-based study. BMC Med 2019; 17: 59
    CrossrefPubMedGoogle Scholar
  • 3 Robert Koch-Institut. GEDA-Studie zur Gesundheit in Deutschland 2012. Im Internet (Stand: 11.03.2021) http://dip21.bun-destag.de/dip21/btd/18/033/1803378.pdf
  • 4 Lupton C, Burd L, Harwood R. Cost of fetal alcohol spectrum disorders. Am J Med Genet C SeminMed Genet 2004; 127C: 42-50
    CrossrefPubMedGoogle Scholar
  • 5 Landgraf MN, Heinen F. Diagnostik Fetaler Alkoholspektrum-störungen in der Kinder- und Jugendmedizin – Empfehlungen für die Praxis gemäß der S3-Leitlinie. MonatsschrKinderheilkd 2016; 165: 786-793
    Google Scholar
  • 6 Astley S. Diagnostic Guide for fetal Alcohol Spectrum Disor-ders: The 4-digit diagnostic Code. Seattle: FAS Diagnostic and Prevention Network, University of Washington; 2004
    Google Scholar
  • 7 Clarren SK, Chudley AE, Wong L. et al Normal distribution of palpebral fissure lengths in Canadian school age children. Can J Clin Pharmacol 2010; 17: e67-e78
    PubMedGoogle Scholar
  • 8 Spohr H-L, Steinhausen HC F. et al alcohol spectrum disorders and their persisting sequelae in adult life. DtschArzteblInt 2008; 105: 693-698
    Google Scholar
  • 9 Landgraf MN, Giese RM, Heinen F. Fetale Alkoholspektrums-törungen – Diagnose, neuropsychologische Testung und symptomorientierte Förderung. Z Kinder Jugendpsychiatr Psy-chother 2017; 45: 104-117
    CrossrefPubMedGoogle Scholar
  • 10 Streissguth AP, Bookstein FL, Barr HM. et al Risk factors for ad-verse life outcomes in fetal alcohol syndrome and fetal alcohol effects. J Dev BehavPediatr 2004; 25: 228-238
    Google Scholar
  • 11 OʼConnor MJ, Portnoff LC, Lebsack-Coleman M. et al Suicide risk in adolescents with fetal alcohol spectrum disorders. Birth Defects Res 2019; 111: 822-828
    CrossrefPubMedGoogle Scholar
  • 12 Popova S, Lange S, Shield K. et al Comorbidity of fetal alcohol spectrum disorder: a systematic review and meta-analysis. Lancet 2016; 387: 978-987
    CrossrefPubMedGoogle Scholar
  • 13 Kodituwakku PW. A neurodevelopmental framework for the development of interventions for children with fetal alcohol spectrum disorders. Alcohol 2010; 44: 717-728
    CrossrefPubMedGoogle Scholar
  • 14 Patrenko CL, Tahir N, Mahoney EC. et al A qualitative assess-ment of program characteristics for preventing secondary conditions in individuals with fetal alcohol spectrum disorders. J PopulTherClinPharmacol 2014; 21: e246-e259
    Google Scholar
  • 15 Landgraf MN, Hoff T. Fetale Alkoholspektrumstörungen: Diag-nostik, Therapie, Prävention. Stuttgart: Kohlhammer; 2018
    CrossrefGoogle Scholar
  • 16 Rasmussen C. Executive functioning and working memory in fetal alcohol spectrum disorder. Alcohol Clin Exp Res 2005; 29: 1359-1367
    CrossrefPubMedGoogle Scholar
  • 17 Bertrand J. Interventions for Children with Fetal Alcohol Spectrum Disorders Research Consortium. Interventions for children with fetal alcohol spectrum disorders (FASDs): over-view of findings for five innovative research projects. Res Dev Disabil 2009; 30: 986-1006
    CrossrefPubMedGoogle Scholar
  • 18 Petrenko CLM, Pandolfino ME, Robinson LK. Findings from the Families on Track Intervention Pilot Trial for children with fetal alcohol spectrum disorders and their families. Alcohol Clin Exp Res 2017; 41: 1340-1351
    CrossrefPubMedGoogle Scholar
  • 19 Leenaars LS, Denys K, Henneveld D. et al The impact of fetal alcohol spectrum disorders on families: evaluation of a family intervention program. Community Ment Health J 2012; 48: 431-435
    CrossrefPubMedGoogle Scholar
  • 20 Kartin D, Grant TM, Streissguth AP. et al Three-year develop-mental outcomes in children with prenatal alcohol and drug exposure. Pediatr Phys Ther 2002; 14: 145-153
    PubMedGoogle Scholar
  • 21 Goh YI, Chudley AE, Clarren SK. et al Development of Canadian screening tools for fetal alcohol spectrum disorder. J PopulTherClinPharmacol 2008; 15: e344-e366
    Google Scholar
  • 22 Kerns KA, MacSween J, Vander Wekken S. et al Investigating the efficacy of an attention training programme in children with foetal alcohol spectrum disorder. Dev Neurorehabil 2010; 13: 413-422
    CrossrefPubMedGoogle Scholar
  • 23 Nash K, Stevens S, Greenbaum R. et al Improving executive functioning in children with fetal alcohol spectrum disorders. Child Neuropsychol 2015; 21: 191-209
    CrossrefPubMedGoogle Scholar
  • 24 Petrenko CL, Alto ME. Interventions in fetal alcohol spectrum disorders: An international perspective. Eur J Med Genet 2017; 60: 79-91
    CrossrefPubMedGoogle Scholar
  • 25 Doig J, McLennan JD, Gibbard WB. Medication effects on symptoms of attention-deficit/hyperactivity disorder in chil-dren with fetal alcohol spectrum disorder. J Child AdolescPsy-chopharmacol 2008; 18: 365-371
    CrossrefPubMedGoogle Scholar
  • 26 Frankel F, Paley B, Marquardt R. et al Stimulants, neuroleptics, and childrenʼs friendship training for children with fetal alco-hol spectrum disorders. J Child AdolescPsychopharmacol 2006; 16: 777-789
    CrossrefPubMedGoogle Scholar